Detection of influenza A(H3N2) viruses exhibiting reduced susceptibility to the novel cap-dependent endonuclease inhibitor baloxavir in Japan, December 2018

• Published in: Euro surveillance : bulletin européen sur les maladies transmissibles Vol. 24; no. 3; p. 1
• Main Authors: Takashita, Emi, Kawakami, Chiharu, Morita, Hiroko, Ogawa, Rie, Fujisaki, Seiichiro, Shirakura, Masayuki, Miura, Hideka, Nakamura, Kazuya, Kishida, Noriko, Kuwahara, Tomoko, Mitamura, Keiko, Abe, Takashi, Ichikawa, Masataka, Yamazaki, Masahiko, Watanabe, Shinji, Odagiri, Takato
• Format: Journal Article
• Language: English
• Published: Sweden Centre Europeen pour la Surveillance Epidemiologique du SIDA (European Centre for the Epidemiological Monitoring of AIDS) 17.01.2019; European Centre for Disease Prevention and Control (ECDC)
• Subjects: Disease control; Drug therapy; Influenza; Medical treatment; Rapid Communication; Japan; cap-dependent endonuclease inhibitor; resistant; baloxavir marboxil; Influenza virus; baloxavir acid

The novel cap-dependent endonuclease inhibitor baloxavir marboxil was approved for the treatment of influenza virus infection in Japan in February 2018. Two influenza A(H3N2) viruses carrying an I38T substitution in the polymerase acidic subunit (PA) were detected in baloxavir-treated children in De...